Last reviewed · How we verify
Homotaurine
At a glance
| Generic name | Homotaurine |
|---|---|
| Also known as | Vivimind |
| Sponsor | Aristotle University Of Thessaloniki |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects (PHASE3)
- Effect of Citicoline/Homotaurine on PERG in Primary Open Angle Glaucoma (NA)
- Effect of Fixed Combination Citicoline Homotaurine and Pyrroloquinoline Quinone on Pattern-electroretinogram in Glaucoma (PHASE3)
- EMuNI Project: Multiple Nonpharmacological Interventions (NA)
- The Effects of Cannabidiol and Homotaurine in Patients With Mild Cognitive Impairment (PHASE4)
- Single Dose Study of ALZ-801 Prototype Tablets (PHASE1)
- Anti-inflammatory Effect of Curcumin, Homotaurine, Vitamin D3 on Human Vitreous in Patients With Diabetic Retinopathy
- Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients With Mild to Moderate Alzheimer's Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Homotaurine CI brief — competitive landscape report
- Homotaurine updates RSS · CI watch RSS
- Aristotle University Of Thessaloniki portfolio CI